Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
BeiGene logo — BeiGene (Beijing) Co., Ltd. is a life sciences biotechnology...

BeiGene

BeiGene (Beijing) Co., Ltd. is a life sciences biotechnology company

Founded 2010 United States Cambridge, United States 2164 employees IPO Total: $6.69B

General Information

Company Name BeiGene
Founded Year 2010
Location United States Cambridge, United States
Employees 2164
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with BeiGene. To contact BeiGene, visit beonemedicines.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BeiGene compare?

A PDF of BeiGene and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BeiGene soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BeiGene

BeiGene, now rebranding as BeOne Medicines Ltd., is a notable player in the life sciences biotechnology sector. Founded in 2010, the company has been instrumental in developing innovative cancer therapies.

The company recently changed the name of its U.S. subsidiary to BeOne Medicines USA, Inc. as part of a strategic move to align with its anticipated global rebranding. The rebranding aims to reinforce its mission to advance medical innovations and collaborate with the global community, with plans to redomicile to Switzerland, contingent upon shareholder consent.

Financially, BeiGene maintains a robust position with a significant investment marked by a $1.00B Post IPO Debt funding received on November 1, 2025. This demonstrates investor confidence in the company's strategic directions and future prospects.

Business keywords: life sciences, innovative medicines, cancer treatment, immuno-oncology, hematology, oncology, targeted therapy, global rebranding, patient partnerships, pharmaceutical development, therapeutic innovation, global healthcare, redomiciliation, shareholder engagement

Services & Products

Cancer Treatment Development
Clinical Research and Trials
Patient Assistance Programs
Biopharmaceutical Manufacturing

Target Customers

Cancer Patients Healthcare Providers Medical Researchers Investors

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt $1.00B -
01 Nov 2025
Post-IPO Equity $885.00M 1
Royalty Pharma
Royalty Pharma
01 Aug 2025
Post-IPO Equity $2.80B 1
Amgen
01 Dec 2019
Secondary Market $903.00M -
01 Aug 2018
Post-IPO Equity $750.00M -
01 Jan 2018
Post-IPO Equity $185.00M -
01 Nov 2016
IPO Undisclosed -
01 Feb 2016
Series B $96.60M 2
Hillhouse Capital Rock Springs Capital
Hillhouse Capital, Rock Springs Capital
01 May 2015
Series A $75.00M 2
CITIC Capital Hillhouse Capital
CITIC Capital, Hillhouse Capital
01 Nov 2014

BeiGene Alternatives & Competitors

View All Alternatives
BeiGene vs
Takeda Oncology
Takeda Oncology United States

We aspire to cure cancer, with inspiration from patients and innovation from everywhere.

1621 employees
Biopharma, Biotechnology
Compare BeiGene vs Takeda Oncology
BeiGene vs
Cullinan Therapeutics
Cullinan Therapeutics United States

Science That Moves

Post-IPO Equity
131 employees
Biopharma, Biotechnology
BeiGene vs
Kestrel Therapeutics
Kestrel Therapeutics United States

We aspire to invent brilliant technologies for difficult cancer targets, beginning with mutant RAS

Series A
23 employees
Biopharma, Biotechnology
View all alternatives

FAQ About BeiGene

BeiGene (Beijing) Co., Ltd. is a life sciences biotechnology company
BeiGene was founded in 2010.
BeiGene is headquartered in Cambridge, United States.
BeiGene has a B2B, B2C and B2D business model. Its revenue comes from Product Sales and Licensing.
BeiGene has approximately 2164 employees.
BeiGene has completed 9 funding rounds, raising a total of $6.69B. The latest funding stage is IPO.
BeiGene offers: Cancer Treatment Development, Clinical Research and Trials, Patient Assistance Programs, Biopharmaceutical Manufacturing.
Top alternatives and competitors to BeiGene include Takeda Oncology, Cullinan Therapeutics, Kestrel Therapeutics, 2seventy bio, Arcellx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BeiGene and Takeda Oncology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BeiGene, https://bouncewatch.com/company/beigene, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes